Vertex Pharmaceuticals (VRTX) Accounts Payables (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Accounts Payables of $489.3 million for Q1 2026, up 9.96% year-over-year from $445.0 million in Q1 2025, and up 5.98% quarter-over-quarter from $461.7 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Accounts Payables (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $489.3 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 9.96% year-over-year to $489.3 million; the TTM figure through Mar 2026 stood at $489.3 million (up 9.96% YoY), while the FY2025 annual figure was $461.7 million, up 11.79% from the prior year.
- Accounts Payables for Q1 2026 stood at $489.3 million, up from $461.7 million in the prior quarter.
- The five-year high for Accounts Payables was $489.3 million in Q1 2026, with the low at $126.9 million in Q3 2022.
- The 5-year median for Accounts Payables is $364.9 million (2023), against an average of $351.5 million.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 196.22% in 2023, then retreated 9.67% in 2024.
- Vertex Pharmaceuticals' Accounts Payables stood at $303.9 million in 2022, then rose by 20.07% to $364.9 million in 2023, then gained by 13.18% to $413.0 million in 2024, then grew by 11.79% to $461.7 million in 2025, then advanced by 5.98% to $489.3 million in 2026.
- Business Quant data shows VRTX's Accounts Payables at $489.3 million in Q1 2026, $461.7 million in Q4 2025, and $420.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 429.50 Mn |
| Mar 31, 2026 | 489.30 Mn |
| Dec 31, 2025 | 461.70 Mn |
| Sep 30, 2025 | 420.30 Mn |
| Jun 30, 2025 | 442.30 Mn |
| Mar 31, 2025 | 445.00 Mn |
| Dec 31, 2024 | 413.00 Mn |
| Sep 30, 2024 | 395.80 Mn |
| Jun 30, 2024 | 327.90 Mn |
| Mar 31, 2024 | 351.40 Mn |
| Dec 31, 2023 | 364.90 Mn |
| Sep 30, 2023 | 375.90 Mn |
| Jun 30, 2023 | 363.00 Mn |
| Mar 31, 2023 | 323.20 Mn |
| Dec 31, 2022 | 303.90 Mn |
| Sep 30, 2022 | 126.90 Mn |
| Jun 30, 2022 | 198.00 Mn |
| Mar 31, 2022 | 173.60 Mn |
| Dec 31, 2021 | 195.00 Mn |
| Sep 30, 2021 | 127.86 Mn |